Abhisek Nayak

Director, Strategic Finance at Dermavant Sciences
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Thousand Oaks, California, United States, US

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
You need to have a working account to view this content.

Experience

    • United States
    • Biotechnology Research
    • 200 - 300 Employee
    • Director, Strategic Finance
      • Apr 2023 - Present

      Long Beach, California, United States

    • United States
    • Biotechnology Research
    • 700 & Above Employee
    • Business Development Sr. Manager
      • Mar 2021 - Apr 2023

      Led valuations and participated in due diligence, negotiations and transaction of all types of BD deals (M&A, Collaborations, out-license etc.). Co-ordinated with other members of the Business Development team as well as relevant business units and/or corporate functions such as Alliance Management, FP&A, Legal and Accounting. •Collaboration deal with Kyowa Kirin for a Ph3 ready inflammation asset •Collaboration deal with Lilly to supply COVID-19 antibody treatment •Collaboration… Show more Led valuations and participated in due diligence, negotiations and transaction of all types of BD deals (M&A, Collaborations, out-license etc.). Co-ordinated with other members of the Business Development team as well as relevant business units and/or corporate functions such as Alliance Management, FP&A, Legal and Accounting. •Collaboration deal with Kyowa Kirin for a Ph3 ready inflammation asset •Collaboration deal with Lilly to supply COVID-19 antibody treatment •Collaboration on a multi-target research deal with Generate Biomedicine •Led Annual Audit Committee Review of recent acquisitions •Supported Amgen Ventures and managed financial performance of Amgen venture investments •Modeled several potential M&A, Collaboration, and Licensing opportunities across various therapeutic areas

    • Sr Finance Manager - S&M FP&A (Global OPEX Consolidation)
      • May 2019 - Mar 2021

      Thousand oaks Led a team responsible for consolidation of worldwide S&M operating expenses. Responsible for all financial deliverables including monthly close, quarterly forecasts, annual budget, and long range plan; prepared materials for earnings call, analysts and investors. •Led consolidation and reporting of worldwide S&M operating expenses (~$4B per year) •Managed three direct reports responsible for financial planning of Global S&M expenses •Supported various works streams aimed at… Show more Led a team responsible for consolidation of worldwide S&M operating expenses. Responsible for all financial deliverables including monthly close, quarterly forecasts, annual budget, and long range plan; prepared materials for earnings call, analysts and investors. •Led consolidation and reporting of worldwide S&M operating expenses (~$4B per year) •Managed three direct reports responsible for financial planning of Global S&M expenses •Supported various works streams aimed at productivity improvements and operating expense savings

    • Sr. Finance Manager, S&M FP&A (US Revenue Planner - Cardiovascular Products)
      • Sep 2017 - May 2019

      Thousand oaks, CA •Led US revenue modelling for cardiovascular products (Repatha® and Corlanor®) •Prepared Gross-to-Net for forecast and long range plan • Worked cross-functionally with marketing, pricing, value & access teams

    • Sr. Finance Manager, R&D FP&A (Oncology Business Unit)
      • May 2015 - Aug 2017

      Thousand Oaks •Provided financial, analytical, and budget support for the oncology pipeline products •Partnered with R&D teams in the US, UK, and Europe to support global development •Supported life cycle management activities, product valuations, and portfolio prioritization •Led integration of Onyx clinical trials into Amgen systems resulting in efficiency gains and cost savings

    • Finance Manager, (Partnership Finance)
      • Jul 2012 - May 2015

      Thousand Oaks, CA •Forecasted Other Revenue and 3rd party Royalty expenses of corporate P&L •Managed Enbrel® Profit share with Pfizer; •Built Profit share models for TEZSPIRE® (AZ) & EVENITY® (UCB) •Led design and implementation on new financial planning system (Hyperion) for partnership activities

    • United States
    • Biotechnology Research
    • 700 & Above Employee
    • Finance Intern, S&M FP&A
      • May 2011 - Aug 2011

      Thousand Oaks

    • Analyst, Life Sciences
      • Apr 2009 - May 2010

    • Research Analyst, Life Sciences
      • Mar 2007 - Mar 2009

    • United States
    • Software Development
    • 1 - 100 Employee
    • Associate
      • Mar 2006 - Mar 2007

Education

  • Emory University - Goizueta Business School
    MBA, Finance & Strategy, Healthcare
    2010 - 2012
  • Jaypee Institute of Information Technology
    Bachelor of Technology, Biotechnology
    2002 - 2006

Community

You need to have a working account to view this content. Click here to join now